Independent educational reference · Research use information Legal disclaimer

CJC No DAC + Ipamorelin

IMPORTANT: Read the Prep & Injection Guide for proper reconstitution, syringe sizing, and injection protocols. Mistakes here can compromise your research.

About CJC No DAC + Ipamorelin (Hulk Blend)

This blend pairs a GHRH analog with a growth hormone secretagogue in a single 5 mg + 5 mg vial. CJC-1295 No DAC (Mod GRF 1-29) stimulates the anterior pituitary to release growth hormone in short pulses that mimic the body’s natural secretion pattern, thanks to its brief half-life. Ipamorelin is a highly selective ghrelin receptor agonist (GHRP class) that triggers GH release without meaningfully raising cortisol or prolactin. Used together, the two act on complementary pathways, amplifying each GH pulse — the synergy behind this blend’s “Hulk” nickname.

Dosing & Reconstitution Guide

— 5 mg + 5 mg Blend Vial —

Reconstitute: Add 2.5 mL (250 units) bacteriostatic water.
Administration: Subcutaneous injection; inject slowly to minimize flushing or a pins-and-needles sensation.
Timing: Best dosed immediately before bedtime, fasted 2–3 hours after your last meal (do not eat afterward). Morning dosing on an empty stomach before breakfast is an acceptable alternative.
Storage: Lyophilized: freeze at −20 °C; reconstituted: refrigerate at 2–8 °C, avoid freeze-thaw cycles.

Schedule: Once-daily injections, 5–7 days per week.
Cycle Length: 12–16 weeks, followed by an 8–16 week washout period.
Goal: Support pulsatile GH release for recovery, body composition, and sleep quality based on preclinical and clinical literature.

Frequency: Inject once daily subcutaneously.

Standard Protocol

Phase Dose Syringe (U-100)
Start of cycle 6 units (0.06 mL), 1x/day 6 units
Titrate up over cycle Up to 15 units (0.15 mL), 1x/day up to 15 units

Begin at 6 units once daily and gradually titrate upward to a maximum of 15 units daily over the course of the cycle, dosing 5–7 days/week.

Maximum Protocol

Phase Dose Syringe (U-100)
Start of cycle 12 units (0.12 mL), 1x/day 12 units
Titrate up over cycle Up to 30 units (0.30 mL), 1x/day up to 30 units

Begin at 12 units once daily and gradually titrate upward to a maximum of 30 units daily over the course of the cycle, dosing 5–7 days/week.

Benefits
  • Promotes fat metabolism (lipolysis).
  • Supports lean muscle preservation and growth.
  • Accelerates tissue healing in muscle, tendon, and ligament.
  • Enhances exercise recovery and repair of training microtrauma.
  • Improves collagen synthesis, supporting skin elasticity.
  • Potential cosmetic / anti-aging applications studied in peptide research.
  • GH release is linked to improved sleep quality.
  • Possible improvements in energy, mood, and recovery from fatigue.
  • Pulsatile release pattern is less likely to cause receptor desensitization than long-acting GHRH analogs.

CJC-1295 DAC vs. No DAC — What’s the Difference?

With DAC

The Drug Affinity Complex binds the peptide to albumin in the blood, extending its half-life to roughly 6–8 days. One injection can elevate GH and IGF-1 for up to a week — but the constant, sustained GH elevation carries a risk of receptor desensitization.

No DAC (this blend)

A shortened version with a half-life of only ~30 minutes, producing a GH pulse lasting 2–3 hours. This mimics the body’s natural pulsatile secretion pattern and is less likely to cause desensitization.

Side Effects

While side effects are not common, you may experience:

  • Injection site reactions (redness, swelling, itching)
  • Water retention (magnesium supplementation may help) and bloating
  • Mild fatigue or lethargy, usually right after dosing
  • Headaches
  • Flushing/heat or a pins-and-needles sensation after dosing (inject slowly to mitigate)
  • Increased hunger (ghrelin receptor stimulation)
  • Nausea, hives, dry mouth, or hyperactivity
  • Uncommon: tingling/numbness in extremities, joint pain or stiffness, lightheadedness
  • Rare: hypersensitivity/allergic reactions; acromegaly-like symptoms only with very high or prolonged misuse

Interactions
  • Blood sugar / insulin: may temporarily reduce insulin sensitivity; monitor carefully if using insulin or oral hypoglycemics (e.g. metformin, sulfonylureas). May worsen insulin resistance.
  • Thyroid medications: GH influences T4→T3 conversion; dose adjustments may be needed.
  • Corticosteroids: high-dose or chronic use (e.g. prednisone, dexamethasone) can blunt GH release and reduce efficacy.
  • Blood pressure medications: GH-induced fluid retention may reduce diuretic effectiveness or worsen BP control; monitor with beta-blockers, ACE inhibitors, ARBs, or calcium channel blockers.
  • Estrogen: can reduce IGF-1 levels, potentially dampening benefits.
  • Anabolic/hormone therapies: concurrent use with testosterone, SARMs, or similar may cause synergistic effects on muscle growth, water retention, or joint stress.
  • Sedatives/alcohol/sleep medications: may compound dizziness or fatigue.

Contraindications
  • Do not use if pregnant or breastfeeding.
  • Do not use with active cancer (including pituitary adenomas).
  • Do not use with untreated hypothyroidism or an unstable thyroid disorder.
  • Do not use with uncontrolled diabetes mellitus; use caution with any blood-sugar regulation issues and monitor closely.
  • Do not use with already-elevated GH/IGF-1 levels or acromegaly.
  • Do not use with advanced chronic kidney disease.
  • Risk of fluid overload, hypertension, or edema in severe cardiovascular disease.
  • Not for use in critically ill patients.
  • Do not use with an allergy to mannitol or other peptide components; discontinue if hypersensitivity develops.

Stacking Suggestions

This blend is itself a synergistic stack of CJC No DAC and Ipamorelin. Common research pairings to extend it include:

  • L-Carnitine – Supports fatty-acid transport and oxidation during recomposition
  • AOD-9604 – Lipolysis support without glycemic impact
  • BPC-157 and/or TB-500 – Connective-tissue, tendon, and joint recovery alongside GH-mediated repair

Research Sources

PubMed-linked citations for verification. Many studies are animal/in-vitro.

  1. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295 in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID: 16352683
  2. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295. J Clin Endocrinol Metab. 2006;91(12):4792-7. PMID: 16968799
  3. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61. PMID: 9849822
  4. The pharmacokinetics, safety and endocrine effects of the ipamorelin, a novel GH-releasing peptide, in human volunteers. Growth Horm IGF Res. 1999;9(2):106-13. PMID: 10373343
  5. GH-releasing activity of ipamorelin, a new synthetic hexapeptide, after intravenous and subcutaneous administration in adult rats. Growth Horm IGF Res. 1999;9(1):25-30. PMID: 10207505
  6. Growth hormone-releasing hormone: clinical studies and therapeutic aspects. Neuroendocrinology. 2008;86(3):163-7. PMID: 17684384

Research Use Only. All information on this page is for educational purposes only and is not medical advice. PepSherpa does not sell peptides. Consult a licensed healthcare provider before making any health decisions. Many of the studies cited are preclinical (animal/in-vitro).

Scroll to Top